Inhaled insulin effects on lung in Type 1 Diabetes

Phase 2, randomised, open-label trial of insulin human in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Pfizer. Primary endpoint: To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12… Started Dec 2004; status: completed.